SCHEMBL3576715

SCHEMBL3576715

CC(C)CCCC(C)CCCC(C)CCCC(C)CCCC(=O)OC[C@H](O)[C@H](O)CO

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 3/20 0.44
LMNA P02545 2/20 0.42
KDM4E B2RXH2 1/20 0.42
DUSP3 P51452 1/20 0.42
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
BLM P54132 1/20 0.41
MAPT P10636 1/20 0.41
PRKCA P17252 3/20 0.38
PTPN2 P17706 1/20 0.37
CDC25B P30305 1/20 0.37
PRKCE Q02156 1/20 0.37
PRKCQ Q04759 1/20 0.37
PRKCD Q05655 1/20 0.37
DGKA P23743 1/20 0.37
CYP3A4 P08684 1/20 0.36
TSHR P16473 1/20 0.36
ATM Q13315 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
FAAH O00519 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23706436 1.00 PTPN1 (0.44) PTPN1LMNAKDM4EDUSP3MEN1
SCHEMBL12992029 1.00 PTPN1 (0.44) PTPN1LMNAKDM4EDUSP3MEN1
SCHEMBL12991895 0.88 BLM (0.41) PTPN1LMNAKDM4EDUSP3MEN1
SCHEMBL3574597 0.88 BLM (0.41) PTPN1LMNAKDM4EDUSP3MEN1
SCHEMBL16221417 0.86 LMNA (0.58) PTPN1LMNAKDM4EDUSP3MEN1
SCHEMBL17554328 0.86 LMNA (0.58) PTPN1LMNAKDM4EDUSP3MEN1
SCHEMBL13277820 0.86 PTPN1 (0.54) PTPN1PTPN2CDC25BDGKA
SCHEMBL13277823 0.86 PTPN1 (0.54) PTPN1PTPN2CDC25BDGKA
SCHEMBL13471300 0.86 PTPN1 (0.54) PTPN1PTPN2CDC25BDGKA
SCHEMBL12633107 0.86 PTPN1 (0.54) PTPN1PTPN2CDC25BDGKA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230105725-A1 HIGHLY SAFE NON-LAMELLAR LIQUID CRYSTAL FORMING COMPOSITION FARNEX INCORPORATED (JP) 2023-04-06 US claimed
CN-115461084-A Non-lamellar liquid crystal forming composition with high safety 法纳克斯株式会社 2022-12-09 CN claimed
EP-4098281-A1 HIGHLY SAFE NON-LAMELLAR LIQUID CRYSTAL FORMING COMPOSITION Farnex Incorporated (JP) 2022-12-07 EP claimed
US-20160067208-A1 ADHESION PREVENTING AGENT FARNEX INCORPORATED (JP) 2016-03-10 US claimed
EP-2992910-A1 ADHESION PREVENTING AGENT Farnex Incorporated (JP) 2016-03-09 EP claimed
US-20230105725-A1 HIGHLY SAFE NON-LAMELLAR LIQUID CRYSTAL FORMING COMPOSITION FARNEX INCORPORATED (JP) 2023-04-06 US disclosed
CN-115461084-A Non-lamellar liquid crystal forming composition with high safety 法纳克斯株式会社 2022-12-09 CN disclosed
EP-4098281-A1 HIGHLY SAFE NON-LAMELLAR LIQUID CRYSTAL FORMING COMPOSITION Farnex Incorporated (JP) 2022-12-07 EP disclosed
US-20160067208-A1 ADHESION PREVENTING AGENT FARNEX INCORPORATED (JP) 2016-03-10 US disclosed
EP-2992910-A1 ADHESION PREVENTING AGENT Farnex Incorporated (JP) 2016-03-09 EP disclosed
US-7846903-B2 cubic liquid crystal formulation containing an amphiphilic compound such as 1-O-(5,9,13-trimethyltetradecyl)erythritol and a drug ( excluding a lysosomal enzyme) or cosmetic embedded in the cubic liquid crystal; time release agent NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) 2010-12-07 US disclosed
US-20080113923-A1 Type II Cubic Liquid Crystal Composition NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE (JP) 2008-05-15 US disclosed
EP-1813287-A1 TYPE II CUBIC LIQUID CRYSTAL COMPOSITION National Institute of Advanced Industrial Science and Technology (JP) 2007-08-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080113923-A1 Type II Cubic Liquid Crystal Composition AQP1, AQP3, SCO2 PTPN1 4309/4885LMNA 1444/4885KDM4E 4665/4885
US-20160067208-A1 ADHESION PREVENTING AGENT EPCAM, ICAM1, VCAM1 PTPN1 1953/4885LMNA 888/4885KDM4E 3962/4885
US-20230105725-A1 HIGHLY SAFE NON-LAMELLAR LIQUID CRYSTAL FORMING COMPOSITION LIPA, PHOSPHO1, PLA2G12A PTPN1 47/4885LMNA 1087/4885KDM4E 4079/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.